Compare Abbott Laboratories (ABT) vs Global Payments Inc (GPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Global Payments Inc — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while Global Payments Inc trades at $73.2 (market cap $21.22B). The key difference: Abbott Laboratories is far larger — about 7.9× Global Payments Inc's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | GPN | |
|---|---|---|
Market Cap | $166.94B | $21.22B |
Sector | Health | Industrials |
52-Week High | $136.62 | $90.01 |
52-Week Low | $82.57 | $62.47 |
Enterprise Value | $193.69B | $38.94B |
Dividend Yield | 2.63% | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
GPN trades at $77.59, down 1.32% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.96 exceeding expectations. Revenue for 2025 was $7.71 billion, though net income margin turned negative at -7.97% for 2026 projections. Analysts maintain a buy consensus with a $80 price target, citing growth from the Worldpay integration and new AI-powered POS launches.
The stock presents a mixed outlook: positive analyst sentiment and strategic expansions support upside, but margin pressures and rising debt pose risks. Investors should weigh the company's innovation against competitive fintech threats and macroeconomic headwinds affecting transaction volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
